U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C11H17BrN
Molecular Weight 243.163
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 1

SHOW SMILES / InChI
Structure of BRETYLIUM

SMILES

CC[N+](C)(C)CC1=C(Br)C=CC=C1

InChI

InChIKey=AAQOQKQBGPPFNS-UHFFFAOYSA-N
InChI=1S/C11H17BrN/c1-4-13(2,3)9-10-7-5-6-8-11(10)12/h5-8H,4,9H2,1-3H3/q+1

HIDE SMILES / InChI
Bretylium (bretylium tosylate) is an antifibrillatory and antiarrhythmic agent. Bretylium is abromobenzyl quaternary ammonium compound which selectively accumulates in sympathetic ganglia and their postganglionic adrenergic neurons where it inhibits norepinephrine release by depressing adrenergic nerve terminal excitability. The drug has a direct positive inotropic effect on the myocardium and blocking effect on postganglionic sympathetic nerve transmission. The drug is poorly absorbed orally, requiring either i.m. or i.v. administration.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
4.5 mM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
BRETYLIUM TOSYLATE

Approved Use

Bretylium (bretylium tosylate injection ) Tosylate is indicated in the prophylaxis and therapy of ventricular fibrillation. Bretylium (bretylium tosylate injection ) tosylate is also indicated in the treatment of life-threatening ventricular arrhythmias, such as ventricular tachycardia, that have failed to respond to adequate doses of a first-line antiarrhythmic agent, such as lidocaine. Use of BRETYLIUM (bretylium tosylate injection ) TOSYLATE INJECTION should be limited to intensive care units, coronary care units or other facilities where equipment and personnel for constant monitoring of cardiac arrhythmias and blood pressure are available. Following injection of BRETYLIUM (bretylium tosylate injection ) TOSYLATE INJECTION there may be a delay of 20 minutes to 2 hours in the onset of antiarrhythmic action, although it appears to act within minutes in ventricular fibrillation. The delay in effect appears to be longer after intramuscular than after intravenous injection.
Primary
BRETYLIUM TOSYLATE

Approved Use

Bretylium (bretylium tosylate injection ) Tosylate is indicated in the prophylaxis and therapy of ventricular fibrillation. Bretylium (bretylium tosylate injection ) tosylate is also indicated in the treatment of life-threatening ventricular arrhythmias, such as ventricular tachycardia, that have failed to respond to adequate doses of a first-line antiarrhythmic agent, such as lidocaine. Use of BRETYLIUM (bretylium tosylate injection ) TOSYLATE INJECTION should be limited to intensive care units, coronary care units or other facilities where equipment and personnel for constant monitoring of cardiac arrhythmias and blood pressure are available. Following injection of BRETYLIUM (bretylium tosylate injection ) TOSYLATE INJECTION there may be a delay of 20 minutes to 2 hours in the onset of antiarrhythmic action, although it appears to act within minutes in ventricular fibrillation. The delay in effect appears to be longer after intramuscular than after intravenous injection.
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1100 ng/mL
100 mg single, intravenous
dose: 100 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
BRETYLIUM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
535 min
100 mg single, intravenous
dose: 100 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
BRETYLIUM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
2500 mg multiple, intravenous
Dose: 2500 mg
Route: intravenous
Route: multiple
Dose: 2500 mg
Sources:
unhealthy, 66±12 years
n = 103
Health Status: unhealthy
Age Group: 66±12 years
Sex: M+F
Population Size: 103
Sources:
Other AEs: Hypotension, Heart block...
Other AEs:
Hypotension (32%)
Heart block (4%)
Congestive heart failure (5%)
Proarrhythmia (3%)
Nausea (6%)
Confusion (4%)
Thrombocytopenia (3%)
Fever (1%)
Diarrhea (5%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Fever 1%
2500 mg multiple, intravenous
Dose: 2500 mg
Route: intravenous
Route: multiple
Dose: 2500 mg
Sources:
unhealthy, 66±12 years
n = 103
Health Status: unhealthy
Age Group: 66±12 years
Sex: M+F
Population Size: 103
Sources:
Proarrhythmia 3%
2500 mg multiple, intravenous
Dose: 2500 mg
Route: intravenous
Route: multiple
Dose: 2500 mg
Sources:
unhealthy, 66±12 years
n = 103
Health Status: unhealthy
Age Group: 66±12 years
Sex: M+F
Population Size: 103
Sources:
Thrombocytopenia 3%
2500 mg multiple, intravenous
Dose: 2500 mg
Route: intravenous
Route: multiple
Dose: 2500 mg
Sources:
unhealthy, 66±12 years
n = 103
Health Status: unhealthy
Age Group: 66±12 years
Sex: M+F
Population Size: 103
Sources:
Hypotension 32%
2500 mg multiple, intravenous
Dose: 2500 mg
Route: intravenous
Route: multiple
Dose: 2500 mg
Sources:
unhealthy, 66±12 years
n = 103
Health Status: unhealthy
Age Group: 66±12 years
Sex: M+F
Population Size: 103
Sources:
Confusion 4%
2500 mg multiple, intravenous
Dose: 2500 mg
Route: intravenous
Route: multiple
Dose: 2500 mg
Sources:
unhealthy, 66±12 years
n = 103
Health Status: unhealthy
Age Group: 66±12 years
Sex: M+F
Population Size: 103
Sources:
Heart block 4%
2500 mg multiple, intravenous
Dose: 2500 mg
Route: intravenous
Route: multiple
Dose: 2500 mg
Sources:
unhealthy, 66±12 years
n = 103
Health Status: unhealthy
Age Group: 66±12 years
Sex: M+F
Population Size: 103
Sources:
Congestive heart failure 5%
2500 mg multiple, intravenous
Dose: 2500 mg
Route: intravenous
Route: multiple
Dose: 2500 mg
Sources:
unhealthy, 66±12 years
n = 103
Health Status: unhealthy
Age Group: 66±12 years
Sex: M+F
Population Size: 103
Sources:
Diarrhea 5%
2500 mg multiple, intravenous
Dose: 2500 mg
Route: intravenous
Route: multiple
Dose: 2500 mg
Sources:
unhealthy, 66±12 years
n = 103
Health Status: unhealthy
Age Group: 66±12 years
Sex: M+F
Population Size: 103
Sources:
Nausea 6%
2500 mg multiple, intravenous
Dose: 2500 mg
Route: intravenous
Route: multiple
Dose: 2500 mg
Sources:
unhealthy, 66±12 years
n = 103
Health Status: unhealthy
Age Group: 66±12 years
Sex: M+F
Population Size: 103
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​

Drug as perpetrator​

Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Use of a cardiocerebral-protective drug cocktail prior to countershock in a porcine model of prolonged ventricular fibrillation.
2001 Dec
Bretylium or 6-OHDA-resistant, action potential-evoked Ca2+ transients in varicosities of the mouse vas deferens.
2002 Apr
Potentially significant drug interactions of class III antiarrhythmic drugs.
2003
Survival and normal neurological outcome after CPR with periodic Gz acceleration and vasopressin.
2003 Feb
How do Belgian mobile intensive care units deal with cardiovascular emergencies?
2003 Jun
Amiodarone and bretylium in the treatment of hypothermic ventricular fibrillation in a canine model.
2003 Mar
Cutaneous active vasodilation in humans during passive heating postexercise.
2003 Sep
Effect of age on cutaneous vasoconstrictor responses to norepinephrine in humans.
2004 Nov
Ca2+ sensitization and the regulation of contractility in rat anococcygeus and retractor penis muscle.
2005 May 15
The involvement of nitric oxide in the cutaneous vasoconstrictor response to local cooling in humans.
2006 Aug 1
Delayed threshold for active cutaneous vasodilation in patients with Type 2 diabetes mellitus.
2006 Feb
Nitric oxide and noradrenaline contribute to the temperature threshold of the axon reflex response to gradual local heating in human skin.
2006 May 1
Adrenergic control of venous capacitance during moderate hypoxia in the rainbow trout (Oncorhynchus mykiss): role of neural and circulating catecholamines.
2006 Sep
Leptin inhibits gastric emptying in rats: role of CCK receptors and vagal afferent fibers.
2007
Cholinergic innervation of the guinea-pig isolated vas deferens.
2007 Dec
The effect of the sympathetic and sensory nervous system on active eustachian tube function in the rat.
2007 Mar
Pharmacotherapy options for complex regional pain syndrome.
2007 May
[Electrical storm].
2007 Nov
Relationship among amiodarone, new class III antiarrhythmics, miscellaneous agents and acquired long QT syndrome.
2008
Criteria for arrhythmogenicity in genetically-modified Langendorff-perfused murine hearts modelling the congenital long QT syndrome type 3 and the Brugada syndrome.
2008 Jan
Investigation of the role of adrenergic and non-nitrergic, non-adrenergic neurotransmission in the sheep isolated internal anal sphincter.
2009 Mar
Survival after prolonged resuscitation with 99 defibrillations due to Torsade De Pointes cardiac electrical storm: a case report.
2010 Feb 6
Cold-induced vasoconstriction at forearm and hand skin sites: the effect of age.
2010 Jul
Increased excitability and spontaneous activity of rat sensory neurons following in vitro stimulation of sympathetic fiber sprouts in the isolated dorsal root ganglion.
2010 Nov
Patents

Sample Use Guides

In Vivo Use Guide
BRETYLIUM (bretylium tosylate injection ) TOSYLATE INJECTION is to be used clinically only for treatment of life-threatening ventricular arrhythmias under constant electrocardiographic monitoring. The clinical use of BRETYLIUM (bretylium tosylate injection ) TOSYLATE INJECTION is for short-term use only. Patients should either be kept supine during the course of bretylium (bretylium tosylate injection ) therapy or be closely observed for postural hypotension. The optimal dose schedule for parenteral administration of the drug has not been determined. There is comparatively little experience with dosages greater than 40mg/kg/day, although such doses have been used without apparent adverse effects. The following schedules are suggested: A. For immediately Life-threatening Ventricular Arrhythmias such as Ventricular Fibrillation or Hemodynamically Unstable Ventricular Tachycardia: Administer undiluted BRETYLIUM (bretylium tosylate injection ) TOSYLATE INJECTION at a dosage of 5mg/kg of body weight by rapid intravenous injection. Other usual cardiopulmonary resuscitative procedures, including electrical cardioversion, should be employed prior to and following the injection in accordance with good medical practice. If ventricular fibrillation persists, the dosage may be increased to 10mg/kg and repeated as necessary. For continuous suppression, dilute Bretylium (bretylium tosylate injection ) Tosylate Injection with Dextrose Injection, USP or Sodium Chloride Injection, USP using the table below and administer the diluted solution as a constant infusion of 1 to 2mg Bretylium (bretylium tosylate injection ) Tosylate Injection per minute, (see Table below). When administering Bretylium (bretylium tosylate injection ) Tosylate Injection (or any potent medication) by continuous intravenous infusion, it is advisable to use a precision volume control device. An alternative maintenance schedule is to infuse the diluted solution at a dosage of 5 to 10mg Bretylium (bretylium tosylate injection ) Tosylate per kg body weight, over a period greater than 8 minutes, every 6 hours. More rapid infusion may cause nausea and vomiting, and in patients older than 65 years, may increase the risk of developing orthostatic hypotension. B. Other ventricular arrhythmias: 1) Intravenous Use: Bretylium (bretylium tosylate injection ) tosylate injection must be diluted as described above before intravenous use. Administer the diluted solution at a dosage of 5 to 10mg bretylium (bretylium tosylate injection ) tosylate per kg of body weight by intravenous infusion over a period greater than 8 minutes. More rapid infusion may cause nausea and vomiting, and in patients older than 65 years, may increase the risk of developing orthostatic hypotension. Subsequent doses may be given at 1 to 2 hour intervals if the arrhythmia persists. 2) For Intramuscular Injection: DO NOT DILUTE BRETYLIUM (bretylium tosylate injection ) TOSYLATE INJECTION PRIOR TO INTRAMUSCULAR INJECTION. Inject 5 to 10mg bretylium (bretylium tosylate injection ) tosylate per kg of body weight. Subsequent doses may be given at 1 to 2 hour intervals if the arrhythmia persists. Thereafter, maintain the same dosage every 6 to 8 hours. Intramuscular injection should not be made directly into or near a major nerve, and the site of injection should be varied on repeated injection. Not more than 5mL should be injected intramuscularly in one site. (See PRECAUTONS) As soon as possible, and when indicated, patients should be changed to an oral antiarrhythmic agent for maintenance therapy.
Route of Administration: Other
bretylium at 1-100 uM prolonged the action potentials of the Wistar Kyoto normotensive rat left ventricular strip.
Name Type Language
BRETYLIUM
VANDF   WHO-DD  
Common Name English
(O-BROMOBENZYL)ETHYLDIMETHYLAMMONIUM
Common Name English
BRETYLIUM [VANDF]
Common Name English
Bretylium [WHO-DD]
Common Name English
BRETYLIUM ION
Common Name English
BENZENEMETHANAMINIUM, 2-BROMO-N-ETHYL-N,N-DIMETHYL-
Systematic Name English
BRETYLIUM CATION
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29713
Created by admin on Fri Dec 15 15:55:14 UTC 2023 , Edited by admin on Fri Dec 15 15:55:14 UTC 2023
Code System Code Type Description
EPA CompTox
DTXSID3046958
Created by admin on Fri Dec 15 15:55:14 UTC 2023 , Edited by admin on Fri Dec 15 15:55:14 UTC 2023
PRIMARY
DRUG CENTRAL
394
Created by admin on Fri Dec 15 15:55:14 UTC 2023 , Edited by admin on Fri Dec 15 15:55:14 UTC 2023
PRIMARY
WIKIPEDIA
BRETYLIUM
Created by admin on Fri Dec 15 15:55:14 UTC 2023 , Edited by admin on Fri Dec 15 15:55:14 UTC 2023
PRIMARY
SMS_ID
100000085141
Created by admin on Fri Dec 15 15:55:14 UTC 2023 , Edited by admin on Fri Dec 15 15:55:14 UTC 2023
PRIMARY
FDA UNII
RZR75EQ2KJ
Created by admin on Fri Dec 15 15:55:14 UTC 2023 , Edited by admin on Fri Dec 15 15:55:14 UTC 2023
PRIMARY
RXCUI
19685
Created by admin on Fri Dec 15 15:55:14 UTC 2023 , Edited by admin on Fri Dec 15 15:55:14 UTC 2023
PRIMARY RxNorm
NCI_THESAURUS
C77300
Created by admin on Fri Dec 15 15:55:14 UTC 2023 , Edited by admin on Fri Dec 15 15:55:14 UTC 2023
PRIMARY
MESH
C045166
Created by admin on Fri Dec 15 15:55:14 UTC 2023 , Edited by admin on Fri Dec 15 15:55:14 UTC 2023
PRIMARY
LACTMED
Bretylium
Created by admin on Fri Dec 15 15:55:14 UTC 2023 , Edited by admin on Fri Dec 15 15:55:14 UTC 2023
PRIMARY
IUPHAR
7130
Created by admin on Fri Dec 15 15:55:14 UTC 2023 , Edited by admin on Fri Dec 15 15:55:14 UTC 2023
PRIMARY
EVMPD
SUB00867MIG
Created by admin on Fri Dec 15 15:55:14 UTC 2023 , Edited by admin on Fri Dec 15 15:55:14 UTC 2023
PRIMARY
DRUG BANK
DB01158
Created by admin on Fri Dec 15 15:55:14 UTC 2023 , Edited by admin on Fri Dec 15 15:55:14 UTC 2023
PRIMARY
PUBCHEM
2431
Created by admin on Fri Dec 15 15:55:14 UTC 2023 , Edited by admin on Fri Dec 15 15:55:14 UTC 2023
PRIMARY
CAS
59-41-6
Created by admin on Fri Dec 15 15:55:14 UTC 2023 , Edited by admin on Fri Dec 15 15:55:14 UTC 2023
PRIMARY